Efficacy of mizoribine for steroid-resistant membranoproliferative glomerulonephritis type III.

摘要

Idiopathic membranoproliferative glomerulonephritis (MPGN) is an uncommon disease, and often progresses to end-stage kidney disease. Recently, several reports have focused on the efficacy of mycophenolate mofetil (MMF) in the treatment of refractory MPGN in adolescents. However, the clinical use of MMF has not yet been approved for indications other than recipients of organ transplantation by the Ministry of Health and Welfare in Japan. On the other hand, mizoribine (MZR), a selective inhibitor of inosine monophosphate dehydrogenase, which has a very similar mechanism of action to that of MMF, has been used successfully, without any serious adverse effects, for the treatment of young patients with lupus nephritis and immunoglobulin A nephropathy.